Indication
Attrogy is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.
Loading your page…
Loading your page…
Amyloid Neuropathies, Familial
Marketing Authorisation Holder: Purpose Pharma International AB
EMA Authorisation: 17/07/2025
INN: diflunisal
AI Drug & Interaction Analysis
Free account required
Ask Osler about Attrogy: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.